Yazar "Tayfur, Muhittin" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim
    Öğe
    The feasibility of anthropometric measurements for evaluation of abdominal obesity in patients with autosomal dominant polycystic kidney disease: A cross-sectional study
    (ARAN EDICIONES, S L, 2022) Özkan, Özlem Persil; Cebeci, Egemen; Sevim, Yonca; Savaş, Yıldıray; Öztürk, Savaş; Tayfur, Muhittin
    Introduction: total kidney volume (TKV) increases in patients with autosomal dominant polycystic kidney disease (ADPKD), which perturbs anthropometric measurements. Objectives: the primary objectives were to investigate the accuracy of waist circumference (WC) and waist-to-hip ratio (WHR) for determining abdominal obesity in patients with ADPKD by comparison with magnetic resonance images. The secondary objectives were to investigate the associations of energy/macronutrient intake with WC and WHR. Methods: sixty patients with ADPKD were recruited from a nephrology outpatient clinic in this cross-sectional study. Main outcome measures were: TKV, total subcutaneous fat (TSF), total intraperitoneal fat (TIF), WC, WHR, body mass index (BMI), skinfold thickness (SFT), and energy/ macronutrient intake. Results: mean age was 48.6 ± 11.3 years, 38 of 60 were women, median TKV was 1486 (IQR, 981-2847) mL. The patients classed as obese by the BMI had higher WC, TSF, TIF, and SFT than did non-obese; however, WHR was similar in obese and non-obese men. In the all-patients group, the WHR of obese and non-obese patients were also similar. TKV was positively correlated with WC and WHR in women, but not in men. In the multivariate analysis, TKV was an independent factor affecting WC and WHR in women. Dietary fat intake was similar in groups with and without abdominal obesity according to WC and WHR. Conclusions: in women with ADPKD, WC and WHR may not be accurate anthropometric measurements for evaluation of abdominal obesity; however, they may be associated with TKV.
  • Küçük Resim Yok
    Öğe
    The role of aspiration therapy and intragastric botulinum toxin A injection in obesity treatment
    (Elsevier Ltd, 2021) Ülger, Taha Gökmen; Tayfur, Muhittin; Çakıroğlu, Funda Pınar
    Aspiration therapy (AT) and intragastric injection of botulinum toxin A (gastric botox) are among the current endoscopic techniques used in the treatment of obesity. Both techniques have been preferred by patients and physicians due to their easy applicability, low risk of complications and reversibility. In this systematic review, it was aimed to assess the role of these techniques in obesity treatment. A comprehensive search of several databases including Cochrane Library, Web of Science and PubMed were conducted. Twenty-six clinical studies (10 studies on AT and 16 studies on gastric botox) were included. According to the obtained results, the effects of gastric botox on gastric emptying rate, appetite and weight loss have not been clarified yet. On the other hand, it is clear that AT is effective in weight loss. However, the complications that AT can cause (cardiac arrhythmia, hypokalemia, hypochloremic hypokalemic metabolic alkalosis) are more serious compared to gastric botox. AT can also cause some eating behavior disorders. Considering the physiological risks associated with AT, it may be important to support patients undergoing AT treatment with some supplements such as potassium chloride. Patients treated with AT should be periodically screened for eating disorders, in addition to medical monitoring. © 2021 Elsevier Ltd
  • Küçük Resim
    Öğe
    The role of duodenal jejunal bypass liner in obesity treatment
    (AMER INST MATHEMATICAL SCIENCES-AIMS, 2021) Tayfur, Muhittin; Özcan, Çiğdem; Çakıroğlu, Funda Pınar; Ülger, Taha Gökmen
    Endoscopic bariatric procedures including Duedenal Jejunal Bypass Liner (DJBL) have become widespread in obesity treatment in recent years. The aim of this systematic review was to assess the role of DJBL in obesity treatment. A comprehensive search of several databases, including Cochrane Library, PubMed, and Web of Science was conducted to December 2020. Twenty-four clinical studies were assessed. According to the results, it is clear that DJBL provides effective weight reduction at 6-12 months and significant improvements in parameters associated with metabolic syndrome and cardiovascular disease. This technique also has potential to reduce comedications in patients with obesity and type 2 diabetes. Although these positive effects of DJBL are clear, its effect on liver, pancreatic functions, and inflammation markers are not clear yet. In addition, the overall and serious complication (gastrointestinal bleeds, pancreatitis, hepatic abscess, obstruction of the sleeve, biliary colic without cholecystitis and cholangitis) rate causing from the DJBL is very high. DJBL has not been approved by the Food and Drug Administration due to the frequency and severity of complications it causes. While it is certain that DJBL has significant effects on obesity and obesity related comorbidities, the safety aspect needs to be improved.